within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AD09_Ganciclovir;

model Ganciclovir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.083333333333333e-06,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 0.0007,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0005,
    k12 = 2.45e-06,
    k21 = 2.45e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ganciclovir</td></tr><tr><td>ATC code:</td><td>S01AD09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ganciclovir is an antiviral medication used mainly to treat cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those with AIDS or organ transplant recipients. It is approved and used today for the treatment and prevention of CMV infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult subjects following intravenous administration; general population including immunocompromised patients.</p><h4>References</h4><ol><li><p>Nguyen, T, et al., &amp; Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. <i>Antimicrobial agents and chemotherapy</i> 65(3) –. DOI:<a href=\"https://doi.org/10.1128/AAC.02254-20\">10.1128/AAC.02254-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33318012/\">https://pubmed.ncbi.nlm.nih.gov/33318012</a></p></li><li><p>Selby, PR, et al., &amp; Roberts, JA (2023). Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Antimicrobial agents and chemotherapy</i> 67(3) e0155022–None. DOI:<a href=\"https://doi.org/10.1128/aac.01550-22\">10.1128/aac.01550-22</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36815858/\">https://pubmed.ncbi.nlm.nih.gov/36815858</a></p></li><li><p>Li, S, et al., &amp; Wang, Y (2020). Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children. <i>Frontiers in pharmacology</i> 11 614164–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2020.614164\">10.3389/fphar.2020.614164</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33536921/\">https://pubmed.ncbi.nlm.nih.gov/33536921</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AD09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ganciclovir;
